These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20959411)

  • 1. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome.
    Herst PM; Howman RA; Neeson PJ; Berridge MV; Ritchie DS
    J Leukoc Biol; 2011 Jan; 89(1):51-5. PubMed ID: 20959411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
    Wongprajun S; Auewarakul CU
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease.
    Notario A; Rolandi ML; Mazzucchelli I
    Haematologica; 1996; 81(3):261-4. PubMed ID: 8767533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
    Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
    Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
    Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
    Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
    Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
    Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.
    Lu CM; Murata-Collins JL; Wang E; Siddiqi I; Lawrence H
    Am J Hematol; 2006 Dec; 81(12):963-8. PubMed ID: 16917916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.
    Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M
    Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
    Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
    Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.
    Grosicki S; Holowiecki J; Giebel S; Kyrcz-Krzemien S; Kuliczkowski K; Kielbinski M; Skotnicki AB; Piatkowska-Jakubas B; Hellmann A; Wierzbowska A; Stella-Holowiecka B; Zdziarska B; Calbecka M
    Am J Hematol; 2011 May; 86(5):437-9. PubMed ID: 21465518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.